AIDS drugs development

Singh M, Johnson L (2006) Using genetically engineered mouse models of cancer to aid drug development an industry perspective. Clin Cancer Res 12 5312-5328... 

The AIDS crisis led to cooperation between the pharmaceutical companies unparalleled since the development of penicillin during the Second World War. Fifteen companies set up an AIDS drug development collaboration programme and government agencies and universities have all joined in. 

The potential scope of the subject of potential changes —fundamental changes—that would aid drug development is almost limitless. But a focused approach is required if improvements are to be made. And it is essential that interested parties, ranging from patients to Wall Street, recognize each other s points of view and come to this virtual negotiating table without a fully developed and intractable position. ... 

Arno, P., and K. Feiden. Against the Odds The Story of AIDS Drug Development, Politics and Profits. New York HarperCollins Publishers, 1992. 

Mohan P, Baba M, eds. Anti-AIDS drug development challenges, strategies, and prospects. Chur, Switzerland Harwood Academic, 1995. 

Within the pharmaceutical industry we have progressed from the point where computers in the laboratory were rarely present or used beyond spreadsheet calculations. Now computers are ubiquitous in pharmaceutical research and development laboratories, and nearly everyone has at least one used in some way to aid in his or her role. It should come as no surprise that the development of hardware and software over the last 30 years has expanded the scope of computer use to virtually all stages of pharmaceutical research and development (data analysis, data capture, monitoring and decision making). Although there are many excellent books published that are focused on in-depth discussions of computer-aided drug design, bioinformatics, or other related individual topics, none has addressed this broader utilization of... 

Makela and colleagues described the occurrence of a probable recurrent GBS six weeks after initiation of HAART and after a striking increase in CD4 cell count in an HfV-infected individual (Makela et al. 2002). Piliero and colleagues described an HIV-infected patient with AIDS who developed GBS, 26 days after initiation of a 6-drug HAART regimen, which had led to an impressive immune reconstitution (a rise in CD4 cell count from 31 to 602 cells/pL) (Piliero et al. 2003). Puthanakit and colleagues identified a child who developed GBS, 3 weeks after initiation of efavirenz-based HAART in a cohort of HIV-infected Thai children (Puthanakit et al. 2006). 

An analysis of the solubility and absorption rates for the 254 drugs considered here shows that the 25 compounds fulfilling the condition of 0.25a - XQ > 5.0 and HQi > 20.0 have solubility of only a few micrograms per milHHter, and are absorbed at the level of only a few percents. Such properties are too poor for drug development, so these parameters can be useful as an alert in computer-aided compound selection. 

Talevi A. Bellera C.L. Di Ianni M. Duchowicz P.R. Bruno-Blanch L.E. Castro E.A. An Integrated drug development approach applying topological descriptors. Current Computer-Aided Drug Design, 2012, 8 (3), 172-181. 

---